ArticleDiscover oncology2026
SOX30 is a diagnostic biomarker that suppresses ovarian cancer progression through an autophagy mediated mechanism.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe discovery and identification of novel diagnostic markers and effective therapeutic targets for ovarian cancer are urgently required. Recent studies have demonstrated that SOX30 suppresses tumor metastasis and serves as a prognostic and chemotherapeutic marker in advanced-stage ovarian cancer. In this study, we aim to investigate the expression patterns, regulatory mechanisms, and diagnostic potential of SOX30, as well as its SOX30 in tumor growth and the underlying mechanisms in ovarian cancer.
methodsUsing data from The Cancer Genome Atlas (TCGA) database, we comprehensively analyzed the association between SOX30 expression levels and copy number variations (CNVs) as well as DNA methylation in ovarian cancer. The functional role of SOX30 in tumor growth was evaluated through MTS assays, colony formation assays, rescue experiments, and xenograft models. Flow cytometry, western blotting, and confocal microscopy were employed to explore the effects of SOX30 on apoptosis and autophagy. Additionally, co-expression analysis of SOX30-related genes and functional enrichment analysis were performed to uncover potential biological pathways.
resultsSOX30 was frequently overexpressed in ovarian cancer, closely associated with copy number amplification, and effectively distinguished tumor tissues from normal tissues. Functionally, SOX30 significantly inhibited cancer cell proliferation in vitro and suppressed tumor growth in vivo, inducting slight cell apoptosis but marked autophagy in ovarian cancer cells. Mechanistically, the inhibitory effect of SOX30 on cancer cell proliferation was dependent on the regulation of autophagy. At the molecular level, SOX30 modulated biological processes and signaling pathways related to autophagy rather than apoptosis in ovarian cancer. Furthermore, SOX30 showed a strong positive correlation with key autophagy-related genes in ovarian cancer.
conclusionsOur findings identify SOX30 as a promising diagnostic marker and therapeutic target in ovarian cancer, and highlight the previously underappreciated role of SOX30 in suppressing cancer cell proliferation and tumor growth primarily through an autophagy-mediated mechanism, offering new insights into the pathogenesis and treatment of ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.